The last time I spoke about Absci Corporation (ABSI), it was in a Seeking Alpha article entitled "Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile." The hope here ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

According to TipRanks.com, Blum is a 5-star analyst with an average return of 14.1% and a 44.6% success rate. Blum covers the Healthcare sector, focusing on stocks such as Artiva Biotherapeutics, Inc.

Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...

Fifth-generation AMD EPYC processors and RDMA cluster networking power OCI’s bare metal instances. They provide Absci with the low-latency networking and throughput required for large-scale model ...

Absci CEO Sean McClain Absci says it is about a year away from its lead AI-designed therapeutic entering the clinic—one of several pipeline candidates whose development the company says it will be ...